ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France. Show more
Location: 7-11 boulevard Haussmann, Paris, 75009, France | Website: https://www.abivax.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
6.424B
52 Wk Range
$4.77 - $92.91
Previous Close
$82.55
Open
$83.00
Volume
636,543
Day Range
$81.03 - $84.50
Enterprise Value
6.568B
Cash
60.95M
Avg Qtr Burn
-33.88M
Insider Ownership
0.00%
Institutional Own.
43.34%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Obefazimod Details Moderately to Severely Active Ulcerative Colitis | Phase 3 Data readout | |
Obefazimod Details Crohn’s Disease | Phase 2b Data readout |